LIFE - aTyr pharma records last patient visit in early-stage ATYR1923 pulmonary sarcoidosis trial

aTyr Pharma (LIFE) announces that the last patient has completed their last visit in the company’s Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease.The company expects to report results from the trial in September 2021.The trial is a multiple-ascending dose, double-blind, placebo-controlled study in 37 patients with pulmonary sarcoidosis that was designed to evaluate the safety, tolerability, immunogenicity and pharmacokinetic profile of multiple doses of ATYR1923 compared to placebo.It also looks to evaluate preliminary efficacy measures including steroid sparing effect, measures of lung function and potential disease biomarkers.Shares up nearly 3% premarket.

For further details see:

aTyr pharma records last patient visit in early-stage ATYR1923 pulmonary sarcoidosis trial